莫索尼定

Moxonidine
75438-57-2

陕西更新日期：2019-11-08

XI’AN WANLONG PHARMACEUTICAL CO.,LTD

非会员

联系人：raffia chou

电话：029-81881044拨打

手机：13259794374 拨打

邮箱：raffiachou@hotmail.com

产品详情:

中文名称：: 莫索尼定

英文名称：: Moxonidine

CAS号：: 75438-57-2

产地：: 陕西、西安

纯度规格：: ≥99%

Product Name:Moxonidine

Synonyms:MOXONIDINE HCL; 4-chloro-n-(4,5-dihydro-1h-imidazol-2-yl)-6-methoxy-2-methyl-5-pyrimidinamin; bdf5895; be5895; BDF-5895 HCL; 4-CHLORO-6-METHOXY-2-METHYL-5-(2-IMIDAZOLIN-2-YL)AMINOPYRIMIDINE HCL; 4-CHLORO-N-(4,5-DIHYDRO-1H-IMIDAZOL-2-YL)-6-METHOXY-2-METHYL-5-PYRIMIDINAMINE HYDROCHLORIDE

CAS RN.: 75438-57-2

Molecular Weight:241.68

Molecular Formula: C₉H₁₂ClN₅O

Density: 1.52g/cm³

Boiling Point(°C): 364.7°C at 760 mmHg

Flash Point(°C): 174.3°C

refractive_index: 1.68

Moxonidine；API;avtive pharmaceutical ingredients

公司简介

Xi’an Wanlong pharmaceutical Co., Ltd was founded in 1995 and it is comprehensive modern pharmaceutical enterprise which mainly produces formulations, API and intermediates. The company’s registered capital reaches CNY 75 million. The building area of company is over 2000000 square meters. All the work shops are compliant with GMP requirements. There are more than 700 employees including over 70 RD staffs，20 experienced production management people and 8 senior professional registration specialists. Having a dynamic, high-quality team, which ensures our company sustainable and stable development. We produce tablets, capsule, granules, injection and API, total 49 drug approval numbers and other intermediates. There are 4 API workshops, and two solid preparation plants, injection plants with GMP. Annual production capacity of 100 tons of raw material, solid dosage form annual output of 3 billion, injection annual output 1.3 billion bags. The drug products are widely used in the most

成立日期	(30年)
注册资本	7500.000000万
员工人数	500人以上
年营业额	￥ 1亿以上
经营模式	工厂
主营行业	医药中间体,原料药